Burning Rock Biotech Limited American Depositary Shares (BNR) is a publicly traded Healthcare sector company. As of May 21, 2026, BNR trades at $17.25 with a market cap of $176.12M and a P/E ratio of 0.00. BNR moved +0.00% today. Year to date, BNR is -31.78%; over the trailing twelve months it is +473.88%. Its 52-week range spans $2.18 to $41.72. Rallies surfaces BNR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Burning Rock Secures USPTO Patent, Q4 Revenue Steady at RMB126.3M: Burning Rock’s ELSA-seq ultrasensitive detection technology secured USPTO patent US 12460202 B2 and its OncoScreen BCMatch Tissue Kit entered priority review at China’s NMPA. In Q4 2025, revenue held steady at RMB126.3M while gross margin rose to 78.0% and net loss shrank to RMB15.4M from RMB81.3M a year earlier.
| Metric | Value |
|---|---|
| Price | $17.25 |
| Market Cap | $176.12M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $41.72 |
| 52-Week Low | $2.18 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
BNR analyst coverage data. Average price target: $0.00.